324 related articles for article (PubMed ID: 25586015)
1. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
Cortes JE; Kantarjian HM; Rea D; Wetzler M; Lipton JH; Akard L; Khoury HJ; Michallet M; Guerci-Bresler A; Chuah C; Hellmann A; Digumarti R; Parikh PM; Legros L; Warzocha K; Baccarani M; Li E; Munteanu M; Nicolini FE
Cancer; 2015 May; 121(10):1637-44. PubMed ID: 25586015
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
Cortes J; Digumarti R; Parikh PM; Wetzler M; Lipton JH; Hochhaus A; Craig AR; Benichou AC; Nicolini FE; Kantarjian HM;
Am J Hematol; 2013 May; 88(5):350-4. PubMed ID: 23468307
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
Cortes JE; Nicolini FE; Wetzler M; Lipton JH; Akard L; Craig A; Nanda N; Benichou AC; Leonoudakis J; Khoury HJ; Hochhaus A; Baccarani M; Kantarjian HM
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):584-91. PubMed ID: 23787123
[TBL] [Abstract][Full Text] [Related]
4. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.
Akard L; Kantarjian HM; Nicolini FE; Wetzler M; Lipton JH; Baccarani M; Jean Khoury H; Kurtin S; Li E; Munteanu M; Cortes J
Leuk Lymphoma; 2016; 57(3):654-65. PubMed ID: 26436949
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
Cortes J; Lipton JH; Rea D; Digumarti R; Chuah C; Nanda N; Benichou AC; Craig AR; Michallet M; Nicolini FE; Kantarjian H;
Blood; 2012 Sep; 120(13):2573-80. PubMed ID: 22896000
[TBL] [Abstract][Full Text] [Related]
6. Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.
Chung C
Am J Health Syst Pharm; 2014 Feb; 71(4):279-88. PubMed ID: 24481153
[TBL] [Abstract][Full Text] [Related]
7. U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.
Alvandi F; Kwitkowski VE; Ko CW; Rothmann MD; Ricci S; Saber H; Ghosh D; Brown J; Pfeiler E; Chikhale E; Grillo J; Bullock J; Kane R; Kaminskas E; Farrell AT; Pazdur R
Oncologist; 2014 Jan; 19(1):94-9. PubMed ID: 24309980
[TBL] [Abstract][Full Text] [Related]
8. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.
Khoury HJ; Cortes J; Baccarani M; Wetzler M; Masszi T; Digumarti R; Craig A; Benichou AC; Akard L
Leuk Lymphoma; 2015 Jan; 56(1):120-7. PubMed ID: 24650054
[TBL] [Abstract][Full Text] [Related]
9. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
[TBL] [Abstract][Full Text] [Related]
10. A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Damlaj M; Lipton JH; Assouline SE
Expert Opin Drug Saf; 2016 Sep; 15(9):1279-86. PubMed ID: 27367461
[TBL] [Abstract][Full Text] [Related]
11. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.
Nicolini FE; Khoury HJ; Akard L; Rea D; Kantarjian H; Baccarani M; Leonoudakis J; Craig A; Benichou AC; Cortes J
Haematologica; 2013 Jul; 98(7):e78-9. PubMed ID: 23753022
[No Abstract] [Full Text] [Related]
12. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
14. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
Boddu P; Shah AR; Borthakur G; Verstovsek S; Garcia-Manero G; Daver N; Kadia T; Ravandi F; Jain N; Alhuraiji A; Burger J; Kornblau S; Pierce S; Dellasala S; Jabbour E; Kantarjian H; Cortes J
Leuk Lymphoma; 2018 Jun; 59(6):1312-1322. PubMed ID: 28972430
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: review and perspectives.
Heiblig M; Sobh M; Nicolini FE
Leuk Res; 2014 Oct; 38(10):1145-53. PubMed ID: 24906663
[TBL] [Abstract][Full Text] [Related]
16. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q; Li Z; Qin Y; Li W; Xu N; Liu B; Zhang Y; Meng L; Zhu H; Du X; Chen S; Liang Y; Hu Y; Liu X; Song Y; Men L; Chen Z; Niu Q; Wang H; Lu M; Yang D; Zhai Y; Huang X
J Hematol Oncol; 2022 Aug; 15(1):113. PubMed ID: 35982483
[TBL] [Abstract][Full Text] [Related]
17. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
Cortes JE; Hochhaus A; le Coutre PD; Rosti G; Pinilla-Ibarz J; Jabbour E; Gillis K; Woodman RC; Blakesley RE; Giles FJ; Kantarjian HM; Baccarani M
Blood; 2011 May; 117(21):5600-6. PubMed ID: 21467546
[TBL] [Abstract][Full Text] [Related]
18. [Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib].
Huang XJ; Hu JD; Li JY; Jin J; Meng FY; Shen ZX; Liu T; Wu DP; Wang JM; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):889-95. PubMed ID: 23363742
[TBL] [Abstract][Full Text] [Related]
19. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Smith TL; Cortes J; Giles FJ; Rios MB; Mallard S; Gajewski J; Murgo A; Cheson B; O'Brien S
J Clin Oncol; 2000 Oct; 18(20):3513-21. PubMed ID: 11032593
[TBL] [Abstract][Full Text] [Related]
20. Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?
Visani G; Isidori A
Expert Opin Pharmacother; 2014 Jan; 15(1):1-3. PubMed ID: 24152096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
